Diabetes is associated with lower global cognitive function in schizophrenia

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 183-187

  Takayanagi, Yoichiro ^a   Cascella, Nicola G ^b   Sawa, Akira ^c   Eaton, William W ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b SHEPPARD PRATT HEALTH SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive function; Diabetes; Insulin resistance; Metabolic syndrome; Physical comorbidity; Schizophrenia

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; TOLAZAMIDE;

ADULT; AGED; ALERTNESS; ARTICLE; BODY MASS; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; OBESITY; PRIORITY JOURNAL; PROGNOSIS; REASONING; SCHIZOPHRENIA; VELOCITY; VERBAL MEMORY; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; ATTENTION; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; MALE; MEMORY, SHORT-TERM; METABOLIC DISEASES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROBLEM SOLVING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84869883272     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.08.034     Document Type: Article

References (34)

1. American Diabetes Association Standards of medical care in diabetes-2011. Diabetes Care 2011, 34(Suppl. 1):S11-S61.
2. Bergman R.N., Ader M. Atypical antipsychotics and glucose homeostasis. J. Clin. Psychiatry 2005, 66(4):504-514.
3. Chien I.C., Hsu J.H., Lin C.H., Bih S.H., Chou Y.J., Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based national health insurance study. Schizophr. Res. 2009, 111(1-3):17-22.
4. Cohen D., Stolk R.P., Grobbee D.E., Gispen-de Wied C.C. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care 2006, 29(4):786-791.
5. Dickinson D., Gold J.M., Dickerson F.B., Medoff D., Dixon L.B. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49(2):123-131.
6. Fagiolini A., Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J. Clin. Psychiatry 2009, 70(Suppl. 3):22-29.
7. Fernandez-Egea E., Bernardo M., Donner T., Conget I., Parellada E., Justicia A., Esmatjes E., Garcia-Rizo C., Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br. J. Psychiatry 2009, 194(5):434-438.
8. Friedman J.I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., Gottlieb S., Harvey P.D., McGinn T.G., Flanagan L., et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am. J. Psychiatry 2010, 167(10):1232-1239.
9. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., Kosten T.R., Wexler B.E. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26(1):75-85.
10. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80(1):45-53.
11. Guo J.J., Keck P.E., Corey-Lisle P.K., Li H., Jiang D., Jang R., L'Italien G.J. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study. J. Clin. Psychiatry 2006, 67(7):1055-1061.
12. Heald A. Physical health in schizophrenia: a challenge for antipsychotic therapy. Eur. Psychiatry 2010, 25(Suppl. 2):S6-S11.
13. Henderson D.C., Borba C.P., Daley T.B., Boxill R., Nguyen D.D., Culhane M.A., Louie P., Cather C., Eden Evins A., Freudenreich O., et al. Dietary intake profile of patients with schizophrenia. Ann. Clin. Psychiatry 2006, 18(2):99-105.
14. Juvonen H., Reunanen A., Haukka J., Muhonen M., Suvisaari J., Arajarvi R., Partonen T., Lonnqvist J. Incidence of schizophrenia in a nationwide cohort of patients with type 1 diabetes mellitus. Arch. Gen. Psychiatry 2007, 64(8):894-899.
15. Keefe R.S., Mohs R.C., Bilder R.M., Harvey P.D., Green M.F., Meltzer H.Y., Gold J.M., Sano M. Neurocognitive assessment in the clinical antipsychotic trials of intervention effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophr. Bull. 2003, 29(1):45-55.
16. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31(9):2033-2046.
17. Kirkpatrick B., Miller B.J., Garcia-Rizo C., Fernandez-Egea E., Bernardo M. Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits?. Schizophr. Bull. 2012, 38(2):280-284. (Mar).
18. Lambert B.L., Cunningham F.E., Miller D.R., Dalack G.W., Hur K. Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am. J. Epidemiol. 2006, 164(7):672-681.
19. Levin E.D., Wilson W., Rose J.E., McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996, 15(5):429-436.
20. Lin P.I., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 2010, 123(2-3):234-243.
21. Miller D.D., McEvoy J.P., Davis S.M., Caroff S.N., Saltz B.L., Chakos M.H., Swartz M.S., Keefe R.S., Rosenheck R.A., Stroup T.S., et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res. 2005, 80(1):33-43.
22. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59(4):337-345.
23. Okumura Y., Ito H., Kobayashi M., Mayahara K., Matsumoto Y., Hirakawa J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. Schizophr. Res. 2010, 119(1-3):145-152.
24. Philippe A., Vaiva G., Casadebaig F. Data on diabetes from the French cohort study in schizophrenia. Eur. Psychiatry 2005, 20(Suppl. 4):S340-S344.
25. Rajji T.K., Ismail Z., Mulsant B.H. Age at onset and cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 2009, 195(4):286-293.
26. Reijmer Y.D., van den Berg E., Ruis C., Kappelle L.J., Biessels G.J. Cognitive dysfunction in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 2010, 26(7):507-519.
27. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
28. Sacco K.A., Termine A., Seyal A., Dudas M.M., Vessicchio J.C., Krishnan-Sarin S., Jatlow P.I., Wexler B.E., George T.P. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch. Gen. Psychiatry 2005, 62(6):649-659.
29. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Diabetes and schizophrenia - effect of disease or drug? results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr. Scand. 2008, 117(5):342-347.
30. Smith R.C., Warner-Cohen J., Matute M., Butler E., Kelly E., Vaidhyanathaswamy S., Khan A. Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 2006, 31(3):637-643.
31. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24(5):481-485.
32. Strachan M.W., Reynolds R.M., Marioni R.E., Price J.F. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 2011, 7(2):108-114.
33. Suvisaari J., Perala J., Saarni S.I., Harkanen T., Pirkola S., Joukamaa M., Koskinen S., Lonnqvist J., Reunanen A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur. Arch. Psychiatry Clin. Neurosci. 2008, 258(3):129-136.
34. van den Berg E., Kloppenborg R.P., Kessels R.P., Kappelle L.J., Biessels G.J. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim. Biophys. Acta 2009, 1792(5):470-481.